Abraxis Oncology Names Joseph Hogan Vice President of U.S. Sales and Marketing

American BioScience Inc. and American PharmaceuticalPartners, Inc. (NASDAQ:APPX) today announced the appointment of JosephHogan to the new position of vice president of U.S. sales andmarketing for Abraxis(TM) Oncology. Hogan will be responsible forleading the U.S. sales and marketing teams for ABRAXANE(R) forInjectable Suspension (paclitaxel protein-bound particles forinjectable suspension) (albumin-bound) and will be reporting to BarryFlannelly, Pharm.D, global vice president of sales and marketing. Atthe close of the merger between American Pharmaceutical Partners (APP)and American BioScience (ABI) in the second quarter of this year,Abraxis Oncology will become a division of Abraxis BioScience, a fullyintegrated global biopharmaceutical company.

"We are fortunate to have Joe join the Abraxis Oncology team. Hisexperience and deep understanding of the needs of cancer patients willbe invaluable as we work toward transforming the way cancer istreated," said Flannelly. "Joe will play a critical role in theexpansion of our U.S. sales and marketing activities that will helpphysicians and patients to better understand the benefits of nextgeneration cancer therapies."

Mr. Hogan brings to Abraxis Oncology extensive expertise in sales,marketing and global brand development in the oncology field. Hoganwas most recently head of global oncology marketing for Berlex. Priorto joining Berlex, he served in numerous leadership positions atSanofi-Aventis, including that of U.S. marketing director forTaxotere(R) where he played a key role in developing brand strategyfor the product in breast, lung and prostate cancers.

About American BioScience, Inc.

American BioScience, Inc. is a privately held biotechnologycompany focused on the discovery, development and delivery ofnext-generation therapeutics including biologically active moleculesalready existing within the human biological system, for the treatmentof life-threatening diseases. ABI owns a majority interest in AmericanPharmaceutical Partners, Inc.

About American Pharmaceutical Partners, Inc.

American Pharmaceutical Partners, Inc. is a specialty drug companythat develops, manufactures and markets injectable pharmaceuticalproducts, focusing on the oncology, anti-infective and critical caremarkets. Abraxis(TM) Oncology, the proprietary division of APP, isdevoted entirely to developing and promoting innovative,next-generation cancer therapies such as ABRAXANE(R) for InjectableSuspension (paclitaxel protein-bound particles for injectablesuspension) (albumin-bound). For more information, visit APP's websiteat www.appdrugs.com and www.abraxisoncology.com.

Taxotere(R) is a registered trademark of Aventis Pharmaceuticals,Inc.